Oruka Therapeutics (NASDAQ:ORKA) Lifted to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Oruka Therapeutics (NASDAQ:ORKA) to a strong-buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.03) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.46) EPS and FY2026 earnings at ($1.92) EPS.

Several other research firms have also recently issued reports on ORKA. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a buy rating and a $40.00 price target for the company. Wedbush started coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They issued an outperform rating and a $40.00 price target for the company. Leerink Partners assumed coverage on Oruka Therapeutics in a report on Tuesday. They set an outperform rating and a $44.00 price objective on the stock. TD Cowen started coverage on Oruka Therapeutics in a report on Monday. They issued a buy rating for the company. Finally, Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research report on Monday. They set an outperform rating and a $41.00 target price on the stock. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of Buy and a consensus target price of $41.25.

Oruka Therapeutics Stock Down 2.2 %

Shares of Oruka Therapeutics stock opened at $24.82 on Tuesday. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.